2017-03-08,Achieve Life Sciences And OncoGenex Pharmaceuticals Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT")
2017-03-01,Achieve Life Science And OncoGenex Pharmaceuticals Announce Strategic Collaboration With The National Institutes Of Health To Advance The Development Of Cytisine For Smoking Cessation
2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
2017-02-16,OncoGenex To Report Year End 2016 Financial Results On Feb. 23, 2017
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-05,OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-03,OncoGenex To Report Third Quarter 2016 Financial Results On Nov. 10, 2016
2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2016-07-21,OncoGenex To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-04-28,OncoGenex To Report First Quarter 2016 Financial Results On May 12, 2016
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-05,OncoGenex Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-02-24,OncoGenex To Report Fourth Quarter And Year End 2015 Financial Results On March 9, 2016
2016-02-04,OncoGenex Announces Reduction In Force To Extend Cash Runway And Align Operations With Clinical Development Priorities
2016-01-20,OncoGenex Announces Update On Phase 2 Spruce Trial In Previously Untreated Metastatic Non-Small Cell Lung Cancer
2016-01-06,4 Stocks Under $10 to Trade for Big Breakouts
2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
2015-11-05,OncoGenex Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-10-29,OncoGenex To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-10-08,OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment
2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
2015-09-23,OncoGenex Announces Phase 2 Rainier Results In Previously Untreated Metastatic Pancreatic Cancer
2015-08-31,OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock
2015-07-30,OncoGenex To Report Second Quarter 2015 Financial Results On August 13, 2015
2015-07-29,OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today
2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-10,FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment
2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
2015-05-20,OncoGenex Announces Data To Be Presented At ASCO 2015 Annual Meeting
2015-05-04,OncoGenex To Report First Quarter 2015 Financial Results On May 14, 2015
2015-04-30,OncoGenex Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC
2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
2015-04-09,OncoGenex Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-23,OncoGenex To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015
2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
2015-02-20,Small-Cap Friday's Little Gem
2015-02-12,OncoGenex Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years
2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2014-12-12,5 Stocks Poised for Breakouts: Trulia and More
2014-11-17,OncoGenex Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference
2014-10-29,Some Of Soros' Stocks Surged Today, While Others Soured
2014-10-16,OncoGenex To Report Financial Results For Third Quarter 2014 On October 30, 2014
2014-09-18,5 Stocks Under $10 to Trade for Breakouts
2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
2014-08-08,4 Stocks Under $10 Making Big Moves
2014-08-07,OncoGenex Pharmaceuticals Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer
2014-07-24,OncoGenex To Report Financial Results For Second Quarter 2014 On August 7, 2014
2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
2014-06-26,OncoGenex Pharmaceuticals Announces Pricing Of $24 Million Underwritten Registered Direct Offering
2014-05-06,The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
2014-05-01,5 Stocks Under $10 Set to Soar
2014-04-28,Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
2014-04-28,OncoGenex To Report Financial Results For First Quarter 2014 On April 30, 2014
2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
2014-03-06,3 Big-Volume Stocks in Breakout Territory
2014-02-25,OncoGenex To Report Financial Results For Fourth Quarter And Year-Ended 2013 On March 11, 2014
2014-02-21,Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
2014-02-06,OncoGenex To Present At Leerink Global Healthcare Investor Conference
2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2013-11-05,OncoGenex To Present At Credit Suisse Healthcare Investor Conference
2013-10-30,OncoGenex To Report Financial Results For Third Quarter 2013 And Address Key Questions From Investors On November 7, 2013
2013-10-25,Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta
2013-10-21,Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)
2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-15,OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)
2013-08-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-08-01,OncoGenex Announces That The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer Is Now Open For Enrollment
2013-07-30,OncoGenex To Webcast Discussion Of Clinical Development Program And Second Quarter 2013 Financial Results On August 8, 2013
2013-07-16,OncoGenex Announces Completion Of Patient Enrollment In The Borealis-1™ Trial Of OGX-427 In Metastatic Bladder Cancer
2013-06-20,Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized
2013-05-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-05-23,OncoGenex Announces Plans For The Initiation Of The Cedar™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer
2013-05-22,OncoGenex Announces Multiple 'Trials In Progress' Presentations At The 2013 ASCO Annual Meeting
2013-05-01,OncoGenex Pharmaceuticals Becomes Oversold (OGXI)
2013-05-01,OncoGenex Announces Plans For The Initiation Of The Rainier™ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2013-04-30,OncoGenex Announces That The Borealis-2™ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment
2013-04-25,OncoGenex To Webcast Discussion Of Clinical Development Program And First Quarter 2013 Financial Results On May 2, 2013
2013-04-23,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-04-11,OncoGenex Announces Plans For The Initiation Of The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer
2013-03-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-02-28,OncoGenex To Webcast Update On Clinical Development Program And Discussion Of Fourth Quarter And Full Year 2012 Financial Results On Thursday, March 7, 2013
2013-02-12,OncoGenex Announces Plans For The Initiation Of The Borealis-2 Clinical Trial Evaluating OGX-427 In Combination With Second-Line Therapy For Bladder Cancer
2013-02-05,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-12-19,OncoGenex Announces Initiation Of Randomized Phase 2 "PACIFIC" Study Of OGX-427 In Combination With Zytiga® In Men With Metastatic Castrate-Resistant Prostate Cancer
2012-11-09,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2012-10-30,OncoGenex To Webcast Discussion Of Third Quarter 2012 Financial Results On Thursday, November 8, 2012
2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
2012-08-28,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-08-07,OncoGenex Announces Initiation Of The Phase 3 "AFFINITY" Trial For Patients With Advanced Prostate Cancer
2012-07-25,OncoGenex To Webcast Discussion Of Second Quarter 2012 Financial Results On Thursday, August 2, 2012
2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
2012-06-04,Data From A Phase 2 Study Presented At The 2012 ASCO Annual Meeting Continues To Show Early Activity Of OGX-427 In Patients With Prostate Cancer
2012-03-27,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-03-23,OncoGenex Pharmaceuticals, Inc. Announces Full Exercise Of Overallotment Option By Underwriters
2012-03-16,OncoGenex Stock Gaps Down On Today's Open (OGXI)
2012-03-16,OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2012-03-15,OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
2012-02-28,OncoGenex To Webcast Discussion Of Fourth Quarter 2011 Financial Results On Thursday, March 8, 2012
2012-02-27,OncoGenex Announces Data Highlighting OGX-427 At 27th Annual European Association Of Urology Congress
2012-02-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-02-02,Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer
2012-02-02,Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer
2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
2011-11-07,Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals
2011-10-26,OncoGenex Announces Publication Of OGX-427 Pre-Clinical Data In Pancreatic Cancer
2011-10-20,OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
2011-10-18,OncoGenex To Webcast Discussion Of Third Quarter Financial Results On Thursday, November 3, 2011
2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2011-09-15,OncoGenex Pharmaceuticals To Present At UBS Global Life Sciences Conference
2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
2011-09-01,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2011-08-10,OncoGenex To Present At The 2011 Wedbush Securities Life Sciences Management Access Conference
2011-07-28,OncoGenex To Webcast Discussion Of Second Quarter Financial Results On Thursday, August 4, 2011
2011-06-28,OncoGenex Pharmaceuticals Added To Russell Indexes
2011-06-07,10 Health-Care Stocks Outperforming the Index
2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
2011-05-17,OncoGenex To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-05-05,9 Health Care Stocks With 100% Buy Ratings
2011-05-02,OncoGenex To Webcast Discussion Of First Quarter Financial Results On Monday, May 9, 2011
2011-04-14,OncoGenex Pharmaceuticals Announces Issuance Of Key European Patent For OGX-427
2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
2011-04-04,OncoGenex Announces Data Highlighting OGX-427 At American Association Of Cancer Research (AACR) 102nd Annual Meeting 2011
2011-03-29,OncoGenex To Present At The Needham & Company 10th Annual Healthcare Conference
2011-03-07,OncoGenex To Webcast Discussion Of Fourth Quarter And Full Year 2010 Financial Results On Thursday, March 10, 2011
2011-02-28,OncoGenex Pharmaceuticals To Participate In Panel Discussion On Novel Cancer Treatments At RBC Capital Markets Healthcare Conference
2011-02-25,Biotech Stock Mailbag: Exact Sciences
2011-02-14,BIO CEO Conference Live Blog
2010-10-19,10 Biotech Stocks Expected to at Least Double
2010-10-11,10 Stocks Expected to Double Amid QE2
2010-05-10,OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
2010-01-11,Looking for a Down Day
2009-12-21,OncoGenex Slammed on Teva Partnership: BioBuzz
2009-12-21,Teva, OncoGenex Sign Drug Development Deal
2009-12-21,Isis Pharmaceuticals To Receive $10 Million From OncoGenex' License Of OGX-011 To Teva
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-10-06,OncoGenex Prostate Cancer Drug Gets Special Review
2009-09-21,Movers Roundup: LivePerson, Tenneco
2009-09-21,OncoGenex Shares Rise On RBC Analyst Outlook
2009-08-25,Movers Roundup: FreightCar America, OncoGenex
2009-08-25,OncoGenex Hits Year High On 'Overweight' Rating
2009-07-10,J&J Finishes Cougar Biotech Deal
2009-05-30,OncoGenex Prostate Drug Extends Survival
2009-05-28,Small-Cap Biotechs Pop Before Conference
2009-05-22,J&J Just Made Medivation's Day
2009-05-22,Biotech Stock Mailbag: Gilead Still Got It?
2009-05-20,Tiny Biotechs Dancing in the Bull Pen
2017-03-08,Achieve Life Sciences And OncoGenex Pharmaceuticals Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT")
2017-03-01,Achieve Life Science And OncoGenex Pharmaceuticals Announce Strategic Collaboration With The National Institutes Of Health To Advance The Development Of Cytisine For Smoking Cessation
2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
2017-02-16,OncoGenex To Report Year End 2016 Financial Results On Feb. 23, 2017
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-05,OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-03,OncoGenex To Report Third Quarter 2016 Financial Results On Nov. 10, 2016
2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2016-07-21,OncoGenex To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-04-28,OncoGenex To Report First Quarter 2016 Financial Results On May 12, 2016
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-05,OncoGenex Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-02-24,OncoGenex To Report Fourth Quarter And Year End 2015 Financial Results On March 9, 2016
2016-02-04,OncoGenex Announces Reduction In Force To Extend Cash Runway And Align Operations With Clinical Development Priorities
2016-01-20,OncoGenex Announces Update On Phase 2 Spruce Trial In Previously Untreated Metastatic Non-Small Cell Lung Cancer
2016-01-06,4 Stocks Under $10 to Trade for Big Breakouts
2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
2015-11-05,OncoGenex Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-10-29,OncoGenex To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-10-08,OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment
2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
2015-09-23,OncoGenex Announces Phase 2 Rainier Results In Previously Untreated Metastatic Pancreatic Cancer
2015-08-31,OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock
2015-07-30,OncoGenex To Report Second Quarter 2015 Financial Results On August 13, 2015
2015-07-29,OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today
2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-10,FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment
2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
2015-05-20,OncoGenex Announces Data To Be Presented At ASCO 2015 Annual Meeting
2015-05-04,OncoGenex To Report First Quarter 2015 Financial Results On May 14, 2015
2015-04-30,OncoGenex Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC
2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
2015-04-09,OncoGenex Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-23,OncoGenex To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015
2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
2015-02-20,Small-Cap Friday's Little Gem
2015-02-12,OncoGenex Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years
2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2014-12-12,5 Stocks Poised for Breakouts: Trulia and More
2014-11-17,OncoGenex Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference
2014-10-29,Some Of Soros' Stocks Surged Today, While Others Soured
2014-10-16,OncoGenex To Report Financial Results For Third Quarter 2014 On October 30, 2014
2014-09-18,5 Stocks Under $10 to Trade for Breakouts
2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
2014-08-08,4 Stocks Under $10 Making Big Moves
2014-08-07,OncoGenex Pharmaceuticals Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer
2014-07-24,OncoGenex To Report Financial Results For Second Quarter 2014 On August 7, 2014
2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
2014-06-26,OncoGenex Pharmaceuticals Announces Pricing Of $24 Million Underwritten Registered Direct Offering
2014-05-06,The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
2014-05-01,5 Stocks Under $10 Set to Soar
2014-04-28,Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
2014-04-28,OncoGenex To Report Financial Results For First Quarter 2014 On April 30, 2014
2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
2014-03-06,3 Big-Volume Stocks in Breakout Territory
2014-02-25,OncoGenex To Report Financial Results For Fourth Quarter And Year-Ended 2013 On March 11, 2014
2014-02-21,Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
2014-02-06,OncoGenex To Present At Leerink Global Healthcare Investor Conference
2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2013-11-05,OncoGenex To Present At Credit Suisse Healthcare Investor Conference
2013-10-30,OncoGenex To Report Financial Results For Third Quarter 2013 And Address Key Questions From Investors On November 7, 2013
2013-10-25,Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta
2013-10-21,Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)
2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-15,OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)
2013-08-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-08-01,OncoGenex Announces That The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer Is Now Open For Enrollment
2013-07-30,OncoGenex To Webcast Discussion Of Clinical Development Program And Second Quarter 2013 Financial Results On August 8, 2013
2013-07-16,OncoGenex Announces Completion Of Patient Enrollment In The Borealis-1™ Trial Of OGX-427 In Metastatic Bladder Cancer
2013-06-20,Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized
2013-05-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-05-23,OncoGenex Announces Plans For The Initiation Of The Cedar™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer
2013-05-22,OncoGenex Announces Multiple 'Trials In Progress' Presentations At The 2013 ASCO Annual Meeting
2013-05-01,OncoGenex Pharmaceuticals Becomes Oversold (OGXI)
2013-05-01,OncoGenex Announces Plans For The Initiation Of The Rainier™ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2013-04-30,OncoGenex Announces That The Borealis-2™ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment
2013-04-25,OncoGenex To Webcast Discussion Of Clinical Development Program And First Quarter 2013 Financial Results On May 2, 2013
2013-04-23,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-04-11,OncoGenex Announces Plans For The Initiation Of The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer
2013-03-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-02-28,OncoGenex To Webcast Update On Clinical Development Program And Discussion Of Fourth Quarter And Full Year 2012 Financial Results On Thursday, March 7, 2013
2013-02-12,OncoGenex Announces Plans For The Initiation Of The Borealis-2 Clinical Trial Evaluating OGX-427 In Combination With Second-Line Therapy For Bladder Cancer
2013-02-05,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-12-19,OncoGenex Announces Initiation Of Randomized Phase 2 "PACIFIC" Study Of OGX-427 In Combination With Zytiga® In Men With Metastatic Castrate-Resistant Prostate Cancer
2012-11-09,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2012-10-30,OncoGenex To Webcast Discussion Of Third Quarter 2012 Financial Results On Thursday, November 8, 2012
2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
2012-08-28,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-08-07,OncoGenex Announces Initiation Of The Phase 3 "AFFINITY" Trial For Patients With Advanced Prostate Cancer
2012-07-25,OncoGenex To Webcast Discussion Of Second Quarter 2012 Financial Results On Thursday, August 2, 2012
2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
2012-06-04,Data From A Phase 2 Study Presented At The 2012 ASCO Annual Meeting Continues To Show Early Activity Of OGX-427 In Patients With Prostate Cancer
2012-03-27,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-03-23,OncoGenex Pharmaceuticals, Inc. Announces Full Exercise Of Overallotment Option By Underwriters
2012-03-16,OncoGenex Stock Gaps Down On Today's Open (OGXI)
2012-03-16,OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2012-03-15,OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
2012-02-28,OncoGenex To Webcast Discussion Of Fourth Quarter 2011 Financial Results On Thursday, March 8, 2012
2012-02-27,OncoGenex Announces Data Highlighting OGX-427 At 27th Annual European Association Of Urology Congress
2012-02-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-02-02,Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer
2012-02-02,Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer
2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
2011-11-07,Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals
2011-10-26,OncoGenex Announces Publication Of OGX-427 Pre-Clinical Data In Pancreatic Cancer
2011-10-20,OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
2011-10-18,OncoGenex To Webcast Discussion Of Third Quarter Financial Results On Thursday, November 3, 2011
2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2011-09-15,OncoGenex Pharmaceuticals To Present At UBS Global Life Sciences Conference
2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
2011-09-01,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2011-08-10,OncoGenex To Present At The 2011 Wedbush Securities Life Sciences Management Access Conference
2011-07-28,OncoGenex To Webcast Discussion Of Second Quarter Financial Results On Thursday, August 4, 2011
2011-06-28,OncoGenex Pharmaceuticals Added To Russell Indexes
2011-06-07,10 Health-Care Stocks Outperforming the Index
2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
2011-05-17,OncoGenex To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-05-05,9 Health Care Stocks With 100% Buy Ratings
2011-05-02,OncoGenex To Webcast Discussion Of First Quarter Financial Results On Monday, May 9, 2011
2011-04-14,OncoGenex Pharmaceuticals Announces Issuance Of Key European Patent For OGX-427
2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
2011-04-04,OncoGenex Announces Data Highlighting OGX-427 At American Association Of Cancer Research (AACR) 102nd Annual Meeting 2011
2011-03-29,OncoGenex To Present At The Needham & Company 10th Annual Healthcare Conference
2011-03-07,OncoGenex To Webcast Discussion Of Fourth Quarter And Full Year 2010 Financial Results On Thursday, March 10, 2011
2011-02-28,OncoGenex Pharmaceuticals To Participate In Panel Discussion On Novel Cancer Treatments At RBC Capital Markets Healthcare Conference
2011-02-25,Biotech Stock Mailbag: Exact Sciences
2011-02-14,BIO CEO Conference Live Blog
2010-10-19,10 Biotech Stocks Expected to at Least Double
2010-10-11,10 Stocks Expected to Double Amid QE2
2010-05-10,OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
2010-01-11,Looking for a Down Day
2009-12-21,OncoGenex Slammed on Teva Partnership: BioBuzz
2009-12-21,Teva, OncoGenex Sign Drug Development Deal
2009-12-21,Isis Pharmaceuticals To Receive $10 Million From OncoGenex' License Of OGX-011 To Teva
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-10-06,OncoGenex Prostate Cancer Drug Gets Special Review
2009-09-21,Movers Roundup: LivePerson, Tenneco
2009-09-21,OncoGenex Shares Rise On RBC Analyst Outlook
2009-08-25,Movers Roundup: FreightCar America, OncoGenex
2009-08-25,OncoGenex Hits Year High On 'Overweight' Rating
2009-07-10,J&J Finishes Cougar Biotech Deal
2009-05-30,OncoGenex Prostate Drug Extends Survival
2009-05-28,Small-Cap Biotechs Pop Before Conference
2009-05-22,J&J Just Made Medivation's Day
2009-05-22,Biotech Stock Mailbag: Gilead Still Got It?
2009-05-20,Tiny Biotechs Dancing in the Bull Pen
2017-03-08,Achieve Life Sciences And OncoGenex Pharmaceuticals Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT")
2017-03-01,Achieve Life Science And OncoGenex Pharmaceuticals Announce Strategic Collaboration With The National Institutes Of Health To Advance The Development Of Cytisine For Smoking Cessation
2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
2017-02-16,OncoGenex To Report Year End 2016 Financial Results On Feb. 23, 2017
2017-01-26,Research Reports Coverage On Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, And AmpliPhi Biosciences
2017-01-05,OncoGenex Pharmaceuticals, Inc. And Achieve Life Science, Inc. Announce Definitive Merger Agreement
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-03,OncoGenex To Report Third Quarter 2016 Financial Results On Nov. 10, 2016
2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2016-07-21,OncoGenex To Report Second Quarter 2016 Financial Results On August 4, 2016
2016-04-28,OncoGenex To Report First Quarter 2016 Financial Results On May 12, 2016
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-05,OncoGenex Pharmaceuticals To Present At The 15th Annual Needham Healthcare Conference
2016-02-24,OncoGenex To Report Fourth Quarter And Year End 2015 Financial Results On March 9, 2016
2016-02-04,OncoGenex Announces Reduction In Force To Extend Cash Runway And Align Operations With Clinical Development Priorities
2016-01-20,OncoGenex Announces Update On Phase 2 Spruce Trial In Previously Untreated Metastatic Non-Small Cell Lung Cancer
2016-01-06,4 Stocks Under $10 to Trade for Big Breakouts
2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
2015-11-05,OncoGenex Pharmaceuticals To Present At The Stifel 2015 Healthcare Conference
2015-10-29,OncoGenex To Report Third Quarter 2015 Financial Results On November 12, 2015
2015-10-08,OncoGenex Announces EMA Support For Phase 3 AFFINITY Trial Protocol Amendment
2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
2015-09-23,OncoGenex Announces Phase 2 Rainier Results In Previously Untreated Metastatic Pancreatic Cancer
2015-08-31,OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock
2015-07-30,OncoGenex To Report Second Quarter 2015 Financial Results On August 13, 2015
2015-07-29,OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today
2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
2015-06-12,Revisiting 2 Little Biotech Gems
2015-06-10,FDA Agrees With OncoGenex' Phase 3 AFFINITY Protocol Amendment
2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
2015-05-20,OncoGenex Announces Data To Be Presented At ASCO 2015 Annual Meeting
2015-05-04,OncoGenex To Report First Quarter 2015 Financial Results On May 14, 2015
2015-04-30,OncoGenex Announces Share Purchase Agreement With Lincoln Park Capital Fund, LLC
2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
2015-04-09,OncoGenex Pharmaceuticals To Present At The 14th Annual Needham Healthcare Conference
2015-03-23,OncoGenex To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015
2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
2015-02-20,Small-Cap Friday's Little Gem
2015-02-12,OncoGenex Announces Relocation Of Corporate Headquarters, Expected To Yield Savings Of At Least $4 Million Over Next Three Years
2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2014-12-12,5 Stocks Poised for Breakouts: Trulia and More
2014-11-17,OncoGenex Pharmaceuticals To Present At The Stifel 2014 Healthcare Conference
2014-10-29,Some Of Soros' Stocks Surged Today, While Others Soured
2014-10-16,OncoGenex To Report Financial Results For Third Quarter 2014 On October 30, 2014
2014-09-18,5 Stocks Under $10 to Trade for Breakouts
2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
2014-08-08,4 Stocks Under $10 Making Big Moves
2014-08-07,OncoGenex Pharmaceuticals Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer
2014-07-24,OncoGenex To Report Financial Results For Second Quarter 2014 On August 7, 2014
2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
2014-06-26,OncoGenex Pharmaceuticals Announces Pricing Of $24 Million Underwritten Registered Direct Offering
2014-05-06,The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
2014-05-01,5 Stocks Under $10 Set to Soar
2014-04-28,Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
2014-04-28,OncoGenex To Report Financial Results For First Quarter 2014 On April 30, 2014
2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
2014-03-06,3 Big-Volume Stocks in Breakout Territory
2014-02-25,OncoGenex To Report Financial Results For Fourth Quarter And Year-Ended 2013 On March 11, 2014
2014-02-21,Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
2014-02-06,OncoGenex To Present At Leerink Global Healthcare Investor Conference
2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
2013-11-05,OncoGenex To Present At Credit Suisse Healthcare Investor Conference
2013-10-30,OncoGenex To Report Financial Results For Third Quarter 2013 And Address Key Questions From Investors On November 7, 2013
2013-10-25,Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta
2013-10-21,Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)
2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
2013-08-15,OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)
2013-08-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-08-01,OncoGenex Announces That The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer Is Now Open For Enrollment
2013-07-30,OncoGenex To Webcast Discussion Of Clinical Development Program And Second Quarter 2013 Financial Results On August 8, 2013
2013-07-16,OncoGenex Announces Completion Of Patient Enrollment In The Borealis-1™ Trial Of OGX-427 In Metastatic Bladder Cancer
2013-06-20,Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized
2013-05-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-05-23,OncoGenex Announces Plans For The Initiation Of The Cedar™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer
2013-05-22,OncoGenex Announces Multiple 'Trials In Progress' Presentations At The 2013 ASCO Annual Meeting
2013-05-01,OncoGenex Pharmaceuticals Becomes Oversold (OGXI)
2013-05-01,OncoGenex Announces Plans For The Initiation Of The Rainier™ Clinical Trial Evaluating OGX-427 In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
2013-04-30,OncoGenex Announces That The Borealis-2™ Clinical Trial Of OGX-427 In Previously Treated Metastatic Bladder Cancer Is Now Open For Enrollment
2013-04-25,OncoGenex To Webcast Discussion Of Clinical Development Program And First Quarter 2013 Financial Results On May 2, 2013
2013-04-23,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-04-11,OncoGenex Announces Plans For The Initiation Of The Spruce™ Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Non-Squamous Non-Small Cell Lung Cancer
2013-03-28,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2013-02-28,OncoGenex To Webcast Update On Clinical Development Program And Discussion Of Fourth Quarter And Full Year 2012 Financial Results On Thursday, March 7, 2013
2013-02-12,OncoGenex Announces Plans For The Initiation Of The Borealis-2 Clinical Trial Evaluating OGX-427 In Combination With Second-Line Therapy For Bladder Cancer
2013-02-05,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-12-19,OncoGenex Announces Initiation Of Randomized Phase 2 "PACIFIC" Study Of OGX-427 In Combination With Zytiga® In Men With Metastatic Castrate-Resistant Prostate Cancer
2012-11-09,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conference
2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2012-10-30,OncoGenex To Webcast Discussion Of Third Quarter 2012 Financial Results On Thursday, November 8, 2012
2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
2012-08-28,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-08-07,OncoGenex Announces Initiation Of The Phase 3 "AFFINITY" Trial For Patients With Advanced Prostate Cancer
2012-07-25,OncoGenex To Webcast Discussion Of Second Quarter 2012 Financial Results On Thursday, August 2, 2012
2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
2012-06-04,Data From A Phase 2 Study Presented At The 2012 ASCO Annual Meeting Continues To Show Early Activity Of OGX-427 In Patients With Prostate Cancer
2012-03-27,OncoGenex Pharmaceuticals To Present At Two Upcoming Investor Conferences
2012-03-23,OncoGenex Pharmaceuticals, Inc. Announces Full Exercise Of Overallotment Option By Underwriters
2012-03-16,OncoGenex Stock Gaps Down On Today's Open (OGXI)
2012-03-16,OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
2012-03-15,OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering Of Common Stock
2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
2012-02-28,OncoGenex To Webcast Discussion Of Fourth Quarter 2011 Financial Results On Thursday, March 8, 2012
2012-02-27,OncoGenex Announces Data Highlighting OGX-427 At 27th Annual European Association Of Urology Congress
2012-02-07,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2012-02-02,Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer
2012-02-02,Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer
2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
2011-11-07,Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals
2011-10-26,OncoGenex Announces Publication Of OGX-427 Pre-Clinical Data In Pancreatic Cancer
2011-10-20,OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
2011-10-18,OncoGenex To Webcast Discussion Of Third Quarter Financial Results On Thursday, November 3, 2011
2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2011-09-15,OncoGenex Pharmaceuticals To Present At UBS Global Life Sciences Conference
2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
2011-09-01,OncoGenex Pharmaceuticals To Present At Upcoming Investor Conferences
2011-08-10,OncoGenex To Present At The 2011 Wedbush Securities Life Sciences Management Access Conference
2011-07-28,OncoGenex To Webcast Discussion Of Second Quarter Financial Results On Thursday, August 4, 2011
2011-06-28,OncoGenex Pharmaceuticals Added To Russell Indexes
2011-06-07,10 Health-Care Stocks Outperforming the Index
2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
2011-05-17,OncoGenex To Present At The UBS Global Specialty Pharmaceuticals Conference
2011-05-05,9 Health Care Stocks With 100% Buy Ratings
2011-05-02,OncoGenex To Webcast Discussion Of First Quarter Financial Results On Monday, May 9, 2011
2011-04-14,OncoGenex Pharmaceuticals Announces Issuance Of Key European Patent For OGX-427
2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
2011-04-04,OncoGenex Announces Data Highlighting OGX-427 At American Association Of Cancer Research (AACR) 102nd Annual Meeting 2011
2011-03-29,OncoGenex To Present At The Needham & Company 10th Annual Healthcare Conference
2011-03-07,OncoGenex To Webcast Discussion Of Fourth Quarter And Full Year 2010 Financial Results On Thursday, March 10, 2011
2011-02-28,OncoGenex Pharmaceuticals To Participate In Panel Discussion On Novel Cancer Treatments At RBC Capital Markets Healthcare Conference
2011-02-25,Biotech Stock Mailbag: Exact Sciences
2011-02-14,BIO CEO Conference Live Blog
2010-10-19,10 Biotech Stocks Expected to at Least Double
2010-10-11,10 Stocks Expected to Double Amid QE2
2010-05-10,OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
2010-01-11,Looking for a Down Day
2009-12-21,OncoGenex Slammed on Teva Partnership: BioBuzz
2009-12-21,Teva, OncoGenex Sign Drug Development Deal
2009-12-21,Isis Pharmaceuticals To Receive $10 Million From OncoGenex' License Of OGX-011 To Teva
2009-10-20,Galleon's Biotech Stock Holdings: BioBuzz
2009-10-06,OncoGenex Prostate Cancer Drug Gets Special Review
2009-09-21,Movers Roundup: LivePerson, Tenneco
2009-09-21,OncoGenex Shares Rise On RBC Analyst Outlook
2009-08-25,Movers Roundup: FreightCar America, OncoGenex
2009-08-25,OncoGenex Hits Year High On 'Overweight' Rating
2009-07-10,J&J Finishes Cougar Biotech Deal
2009-05-30,OncoGenex Prostate Drug Extends Survival
2009-05-28,Small-Cap Biotechs Pop Before Conference
2009-05-22,J&J Just Made Medivation's Day
2009-05-22,Biotech Stock Mailbag: Gilead Still Got It?
2009-05-20,Tiny Biotechs Dancing in the Bull Pen
